Delivery Order SPE2DB20D1100-SPE2DB25FD5E1
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Jardiance 10 mg tablets in a 90-count package. This is a firm fixed-price delivery order with a ceiling value of $6,102.58 and an ultimate completion date of July 21, 2025. The contract utilizes no set-aside designation and represents a competitively awarded procurement. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania....
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $29,954.01 on July 18, 2025, for the supply of Jardiance 25 mg tablets (90-count packages). This firm fixed-price, competitively awarded contract represents a non-set-aside delivery order with an ultimate completion date of July 21, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Jardiance is a diabetes management medication, consistent with...
- The Defense Logistics Agency awarded a delivery order valued at $3,128.96 to AmerisourceBergen Drug Corp for the supply of Jardiance 25 mg tablets (90-count) on July 18, 2025, with an ultimate completion date of July 21, 2025. This competitive award, issued without set-aside designation, represents a firm fixed-price delivery order for pharmaceutical supply fulfillment. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Jardiance 25 mg tablets (90-count units) under a firm fixed price contract valued at $10,700.20. The order, with an ultimate completion date of July 21, 2025, was competitively awarded without set-aside designation. AmerisourceBergen's corporate office in Conshohocken, Pennsylvania will serve as the place of performance for this pharmaceutical supply delivery to support federal medical procurement needs....
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Jardiance 10 mg tablets (90-count) with a ceiling value of $5,395.37. This is a firm fixed-price delivery order with a completion date of July 21, 2025. The contract carries no set-aside designation, indicating competitive award. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for federal medical...
- The Defense Logistics Agency awarded a delivery order valued at $19,208.52 to AmerisourceBergen Drug Corp for the supply of Jardiance 25 mg tablets (90-count units) on July 18, 2025, with a completion date of July 21, 2025. This firm fixed-price delivery order represents a competitively awarded contract with no set-aside designation. The pharmaceutical product will be delivered to AmerisourceBergen's place of performance in Conshohocken, Pennsylvania, where the company maintains its corporate...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Jardiance 25 mg tablets. The contract has a ceiling value of $26,194.07 and a performance period extending through April 11, 2025. It is a firm-fixed-price contract, with no set-aside designation, indicating open competition. AmerisourceBergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support...
- The Defense Logistics Agency (DLA) awarded a $81,903.74 firm fixed price delivery order to AmerisourceBergen Drug Corp for the supply of Jardiance 25 mg tablets (90-count packages) with an ultimate completion date of July 21, 2025. This non-set-aside competitive award is being performed in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with...
- This is a delivery order issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $18,383.60, is for the delivery of Jardiance 10 mg tablets over the period ending January 14, 2025. The award is made under an Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a comprehensive contracting mechanism for the DLA to procure a wide range of...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Jardiance 25 mg tablets. The contract is a firm fixed-price, non-set-aside award with a ceiling value of $3,939.04 and a period of performance through April 23, 2025. AmerisourceBergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999.00, which serves as a...
- SPE2DB20D1100Indefinite Delivery Contract
- SPE2DB20D1100-SPE2DB25FD5E1Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Jardiance 25 mg tablets (90-count units) under a firm fixed-price contract type. The order, valued at $4,520.58, is scheduled for completion by July 21, 2025, and will be fulfilled from the contractor's facility in Conshohocken, Pennsylvania. This delivery order was competitively awarded without set-aside designations, reflecting AmerisourceBergen's established capability to meet federal pharmaceutical procurement requirements through open competition. This order represents a task under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 prime vendor agreement valued through December 2026. As a major pharmaceutical distributor, AmerisourceBergen supplies a comprehensive range of medications and medical supplies to support military and federal healthcare systems globally. Jardiance, an antidiabetic medication, aligns with the company's established portfolio of chronic disease management pharmaceuticals delivered to defense and veteran healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.5k | 7/18/25 |